Promises and challenges of personalized medicine to guide ARDS therapy

Katherine D Wick; Daniel F McAuley; Joseph E Levitt; Jeremy R Beitler; Djillali Annane; Elisabeth D Riviello; Carolyn S Calfee; Michael A Matthay

doi:10.1186/s13054-021-03822-z

Promises and challenges of personalized medicine to guide ARDS therapy

Katherine D Wick, Daniel F McAuley, Joseph E Levitt, Jeremy R Beitler, Djillali Annane, Elisabeth D Riviello, Carolyn S Calfee, Michael A Matthay

Wellcome Wolfson Institute for Experimental Medicine

Research output: Contribution to journal › Article › peer-review

36 Citations (Scopus)

101 Downloads (Pure)

Abstract

Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.

Original language	English
Article number	404
Journal	Critical Care
Volume	25
DOIs	https://doi.org/10.1186/s13054-021-03822-z
Publication status	Published - 23 Nov 2021

Keywords

Acute lung injury
Clinical trials
Acute respiratory distress syndrome
COVID-19
Personalized medicine

Access to Document

10.1186/s13054-021-03822-zLicence: CC BY

Promises and challenges of personalized medicine to guide ARDS therapy
Copyright 2021 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 1.38 MBLicence: CC BY

Cite this

@article{844e300801d5401aae2dfe922f4e8148,

title = "Promises and challenges of personalized medicine to guide ARDS therapy",

abstract = "Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century. ",

keywords = "Acute lung injury, Clinical trials, Acute respiratory distress syndrome, COVID-19, Personalized medicine",

author = "Wick, {Katherine D} and McAuley, {Daniel F} and Levitt, {Joseph E} and Beitler, {Jeremy R} and Djillali Annane and Riviello, {Elisabeth D} and Calfee, {Carolyn S} and Matthay, {Michael A}",

year = "2021",

month = nov,

day = "23",

doi = "10.1186/s13054-021-03822-z",

language = "English",

volume = "25",

journal = "Critical Care",

issn = "1466-609X",

publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Promises and challenges of personalized medicine to guide ARDS therapy

AU - Wick, Katherine D

AU - McAuley, Daniel F

AU - Levitt, Joseph E

AU - Beitler, Jeremy R

AU - Annane, Djillali

AU - Riviello, Elisabeth D

AU - Calfee, Carolyn S

AU - Matthay, Michael A

PY - 2021/11/23

Y1 - 2021/11/23

N2 - Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.

AB - Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.

KW - Acute lung injury

KW - Clinical trials

KW - Acute respiratory distress syndrome

KW - COVID-19

KW - Personalized medicine

U2 - 10.1186/s13054-021-03822-z

DO - 10.1186/s13054-021-03822-z

M3 - Article

C2 - 34814925

SN - 1466-609X

VL - 25

JO - Critical Care

JF - Critical Care

M1 - 404

ER -

Promises and challenges of personalized medicine to guide ARDS therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this